

# NIH Consensus Statement on Celiac Disease



## NIH Consensus and State-of-the-Science Statements

Volume 21, Number 1  
June 28–30, 2004

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
National Institutes of Health  
Office of the Director



## About the NIH Consensus Development Program

NIH Consensus Development and State-of-the-Science Conferences are convened to evaluate the available scientific evidence on a given biomedical or public health topic, often for the purpose of resolving a particular controversial issue in clinical or public health practice. The resulting NIH Consensus and State-of-the-Science Statements are intended to advance understanding of the issue in question and to be useful to health professionals and the public for informed decisionmaking.

NIH Consensus and State-of-the-Science Statements are prepared by independent (non-DHHS) panels of health professionals and public representatives, based on (1) the results of a systematic literature review prepared under contract with the Agency for Healthcare Research and Quality (AHRQ) through its Evidence-based Practice Centers, (2) presentations by investigators working in areas relevant to the conference questions during a 2-day public session, (3) questions and statements from conference attendees during open discussion periods that are part of the public session, and (4) closed deliberations by the panel during the remainder of the second day and morning of the third.

This statement is an independent report of the consensus panel and is not a policy statement of the NIH or the Federal Government. The statement reflects the panel's assessment of medical knowledge available at the time the statement was written. Thus, it provides a "snapshot in time" of the state of knowledge of the conference topic. When reading the statement, keep in mind that new knowledge is inevitably accumulating through medical research.

## Reference Information

For making bibliographic reference to this consensus statement, it is recommended that the following format be used, with or without source abbreviations, but without authorship attribution:

*NIH Consensus Statement on Celiac Disease. NIH Consensus State Sci Statements. 2004 Jun 28–30; 21(1) 1–22.*

## Publications Ordering Information

NIH Consensus Statements, State-of-the-Science Statements, and Technology Assessment Statements and related materials are available by writing to the NIH Consensus Development Program Information Center, P.O. Box 2577, Kensington, MD 20891; by calling toll free **1-888-NIH-CONSENSUS (888-644-2667)**; or by visiting the NIH Consensus Development Program home page at <http://consensus.nih.gov> on the World Wide Web.

The Evidence Report prepared for this conference by the Agency for Healthcare Research and Quality is available on the Web via <http://www.ahrq.gov/clinic/epcix.htm>. Printed copies may be ordered from the AHRQ Publications Clearinghouse by calling 1-800-358-9295. Requestors should ask for AHRQ Publication No. 04-E029-2. An extensive bibliography by the National Library of Medicine is available on the Web at <http://www.nlm.nih.gov/pubs/cbm/celiacdisease.html>.

# NIH Consensus Statement on Celiac Disease

NIH Consensus and State-of-the-Science Statements  
Volume 21, Number 1  
June 28–30, 2004

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
National Institutes of Health  
Office of the Director



## Disclosure Statement

All of the panelists who participated in this conference and contributed to the writing of this statement were identified as having no financial or scientific conflict of interest, and all signed forms attesting to this fact. Unlike the expert speakers who present scientific data at the conference, the individuals invited to participate on NIH Consensus and State-of-the-Science panels are reviewed prior to selection to assure that they are not proponents of an advocacy position with regard to the topic and are not identified with research that could be used to answer the conference questions.

For more information about conference procedures, please see *Guidelines for the Planning and Management of NIH Consensus Development Conferences*, available on the World Wide Web at **<http://consensus.nih.gov/about/process.htm>**.

## Archived Conference Webcast

The NIH Consensus Development Conference on Celiac Disease was webcast live June 28-30, 2004. The webcast is archived and available for viewing free of charge at **[http://consensus.nih.gov/cons/118/118cdc\\_intro.htm](http://consensus.nih.gov/cons/118/118cdc_intro.htm)**.

# Abstract

## Objective

To provide health care providers, patients, and the general public with a responsible assessment of currently available data regarding celiac disease.

## Participants

A non-DHHS, nonadvocate 13-member panel representing the fields of internal medicine, gastroenterology, medical genetics, pathology, endocrinology, nutrition, and a consumer representative. In addition, 19 experts in related fields presented data to the panel and to the conference audience.

## Evidence

Presentations by experts; a systematic review of the medical literature provided by the Agency for Healthcare Research and Quality; and an extensive bibliography of celiac disease research papers, prepared by the National Library of Medicine. Scientific evidence was given precedence over clinical anecdotal experience.

## Conference Process

Answering pre-determined questions, the panel drafted its statement based on scientific evidence presented in open forum and on the published scientific literature. The draft statement was read in its entirety on the final day of the conference and circulated to the audience for comment. The panel then met in executive session to consider the comments received, and released a revised statement later that day at <http://consensus.nih.gov>. This statement is an independent report of the panel and is not a policy statement of the NIH or the Federal Government.

## Conclusions

Celiac disease is an immune-mediated intestinal disorder with protean manifestations. Celiac disease is common, affecting 0.5 to 1.0 percent of the general population of the United States, but is greatly underdiagnosed. There are now specific and sensitive serologic tests available to aid in diagnosis that need to be more widely applied. The treatment of celiac disease remains a lifelong gluten-free diet, which results in remission for most individuals. The classic presentation of diarrhea and malabsorption is less common, and atypical and silent presentations are increasing. Most individuals are being seen by primary care providers and a broad range of specialists. Therefore, heightened awareness of this disease is imperative. Education of physicians, registered dietitians, and other health providers is needed.

The panel recommends the following:

- Education of physicians, dietitians, nurses, and the public about celiac disease by a trans-National Institutes of Health (NIH) initiative, to be led by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in association with the Centers for Disease Control and Prevention.
- Standardization of serologic tests and pathologic criteria for the diagnosis of celiac disease.
- Adoption of a standard definition of a gluten-free diet based on objective evidence such as that being developed by the American Dietetic Association.
- Development of an adequate testing procedure for gluten in foods and definition of standards for gluten-free foods in the United States to lay the foundation for rational food labeling.
- Formation of a federation of celiac disease societies, celiac disease interest groups, individuals with celiac disease and their families, physicians, dietitians, and other health care providers for the advancement of education, research, and advocacy for individuals with celiac disease.

## Introduction

Celiac disease is an immune-mediated disorder that affects primarily the gastrointestinal tract. It is characterized by chronic inflammation of the small intestinal mucosa that may result in atrophy of intestinal villi, malabsorption, and a variety of clinical manifestations, which may begin in either childhood or adult life. Intestinal symptoms can include diarrhea, abdominal cramping, pain, and distention, and untreated celiac disease may lead to vitamin and mineral deficiencies, osteoporosis, and other extraintestinal problems. Considerable scientific progress has been made in understanding celiac disease and in preventing or curing its manifestations by dietary interventions. There is a strong genetic predisposition to celiac disease, with the major risk attributed to the specific genetic markers known as HLA-DQ2 and HLA-DQ8 that are present in affected individuals. Dietary proteins present in wheat, barley, and rye, commonly known as glutes, interact with these HLA molecules to activate an abnormal mucosal immune response and induce tissue damage. Most affected individuals experience remission after excluding gluten from their diet.

Celiac disease has been considered until recently to be a rare disease in the United States. Studies, primarily in Europe but also in the United States, now suggest that its prevalence is much greater than previous estimates, possibly affecting as many as 3 million Americans (roughly 1 percent of the U.S. population), indicating that the disease is widely underrecognized. Recent identification of the autoantigens involved in celiac disease has led to the development of new serologic diagnostic tests, but the appropriate use of these new testing strategies has not been well defined. These tests are identifying many individuals with nonclassical gastrointestinal and extraintestinal symptoms.

As a result of these new developments, and in order to improve awareness, diagnosis, and management of celiac disease, the National Institutes of Health (NIH) convened a Consensus Development Conference on Celiac Disease on June 28–30, 2004. The National Institute of Diabetes and

Digestive and Kidney Diseases (NIDDK) and the Office of Medical Applications of Research (OMAR) of the NIH were the primary sponsors of this meeting. The U.S. Food and Drug Administration, the U.S. Department of Agriculture, the National Institute of Child Health and Human Development, the National Cancer Institute, and the National Institute of Allergy and Infectious Diseases were the cosponsors.

The Agency for Healthcare Research and Quality (AHRQ) supported the NIH Consensus Development Conference on Celiac Disease through its Evidence-based Practice Center (EPC) program. Under contract to the AHRQ, the University of Ottawa EPC developed the systematic review and analysis that served as a reference for discussion at the conference. The National Library of Medicine in collaboration with the University of Ottawa EPC conducted the literature search for the systematic review.

This two-and-a-half-day conference examined the current state of knowledge regarding celiac disease and identified directions for future research. During the first day-and-a-half of the conference, experts presented the latest celiac disease research findings to an independent panel. After weighing this scientific evidence, the panel drafted a statement that addressed the following key questions:

- How is celiac disease diagnosed?
- How prevalent is celiac disease?
- What are the manifestations and long-term consequences of celiac disease?
- Who should be tested for celiac disease?
- What is the management of celiac disease?
- What are the recommendations for future research on celiac disease and related conditions?

On the final day of the conference, the panel chairperson read the draft statement to the conference audience and invited comments and questions. A press conference followed to allow the panel and chairperson to respond to questions from the media.

## How is celiac disease diagnosed?

The single most important step in diagnosing celiac disease is to first consider the disorder by recognizing its myriad clinical features. There is no one test that can definitively diagnose or exclude celiac disease in every individual. Just as there is a clinical spectrum of celiac disease, there is also a continuum of laboratory and histopathologic results. The combination of clinical and laboratory features may result in a diagnosis of celiac disease.

All diagnostic tests need to be performed while the patient is on a gluten-containing diet. The first step in pursuing a diagnosis of celiac disease is a serologic test. Based on very high sensitivities and specificities, the best available tests are the IgA antihuman tissue transglutaminase (TTG) and IgA endomysial antibody immunofluorescence (EMA) tests that appear to have equivalent diagnostic accuracy (TTG is the specific protein that is identified by the IgA-EMA). Antigliadin antibody (AGA) tests are no longer routinely recommended because of their lower sensitivity and specificity. Serologic testing for celiac disease in children less than 5 years of age may be less reliable and requires further study.

Biopsies of the proximal small bowel are indicated in individuals with a positive celiac disease antibody test, except those with biopsy-proven dermatitis herpetiformis. Endoscopic evaluation without biopsies is inadequate to confirm or exclude a diagnosis since endoscopic findings are not sufficiently sensitive for celiac disease. Multiple biopsies should be obtained because the histologic changes may be focal. Biopsies should be obtained from the second portion of the duodenum or beyond. The pathology report should specify the degree of crypt hyperplasia and villous atrophy as well as assess the number of intraepithelial lymphocytes. Some degree of villous atrophy is considered necessary to confirm a diagnosis of celiac disease. The finding of intraepithelial lymphocytes with crypt hyperplasia without villous blunting is less definitive. Standardization of the pathology reports in celiac disease is desirable, using published criteria such

as modified Marsh criteria (1999). Communication between the pathologist and the individual's physician is encouraged to help correlate the biopsy findings with laboratory results and clinical features. Second opinions on biopsy interpretation may be sought when biopsy results are discordant with serologic markers or clinical findings.

With concordant positive serology and biopsy results, a presumptive diagnosis of celiac disease can be made. Definitive diagnosis is confirmed when symptoms resolve subsequently with a gluten-free diet. A demonstration of normalized histology following a gluten-free diet is no longer required for a definitive diagnosis of celiac disease.

In an individual with suggestive symptoms and a negative serology test, three scenarios are possible. First, the individual may have selective IgA deficiency. If an IgA deficiency is identified, an IgG-TTG or IgG-EMA test should be performed. Second, the serologic test may be a "false negative," and if this is suspected the test could be repeated, an alternative serologic test could be conducted, and/or a small intestinal biopsy could be performed. Third, the patient may not have celiac disease.

When the diagnosis of celiac disease is uncertain because of indeterminate results, testing for certain genetic markers (HLA haplotypes) can stratify individuals to high or low risk for celiac disease. Greater than 97 percent of celiac disease individuals have the DQ2 and/or DQ8 marker, compared to about 40 percent of the general population. Therefore, an individual negative for DQ2 or DQ8 is extremely unlikely to have celiac disease (high negative predictive value).

Patient preferences should be elicited in developing recommendations in the setting of a positive celiac disease serology and normal biopsy results. A single best approach cannot be prescribed. Choices include additional small bowel biopsies, periodic monitoring with celiac disease serology tests, or a trial of gluten-free diet.

## How prevalent is celiac disease?

Advances in the understanding of the multisystem nature of celiac disease and the identification of sensitive serologic tests have led to the recognition that celiac disease is much more common than previously thought. Population-based studies in the United States using various combinations of serological testing and small intestinal biopsy suggest that the prevalence of celiac disease is in the range of 0.5 to 1.0 percent, similar to estimates in Europe. These prevalence figures include both symptomatic and asymptomatic individuals. Certain ethnic groups may be at lower risk than Caucasians, but little is known about variation in prevalence among ethnic groups in the United States, a topic needing further study.

Certain populations have an increased prevalence of celiac disease. First-degree relatives of individuals with biopsy-proven celiac disease have a prevalence between 4 and 12 percent of villous atrophy on biopsy. Second-degree relatives also appear to have an increased prevalence, although this has been defined only by serology. People with type 1 diabetes mellitus have a prevalence of biopsy-confirmed celiac disease ranging from 3 to 8 percent. Individuals with Down syndrome have a prevalence of celiac disease ranging from 5 to 12 percent. Celiac disease also is associated with Turner syndrome, Williams syndrome, selective IgA deficiency, and autoimmune disorders.

## What are the manifestations and long-term consequences of celiac disease?

Celiac disease traditionally has been defined as a gastrointestinal malabsorptive disorder that can present early in childhood after the introduction of gluten. It is now recognized, however, that the clinical manifestations are highly variable, may present at any age, and involve multiple organ systems. Prolonged delays in diagnosis are common.

Since celiac disease is a multisystem disorder, the clinical presentation is highly variable. Gastrointestinal manifestations may include diarrhea, weight loss, failure to grow, vomiting, abdominal pain, bloating and distension, anorexia, and constipation. The presence of obesity does not exclude the diagnosis. It is very common for celiac disease to present with extraintestinal manifestations, sometimes with little or no gastrointestinal symptoms. A distinctive example is dermatitis herpetiformis, an intensely pruritic rash on the extensor surfaces of the extremities. Iron deficiency anemia is common and may be the only presenting sign. Other presentations are unexplained short stature, delayed puberty, infertility, recurrent fetal loss, osteoporosis, vitamin deficiencies, fatigue, protein calorie malnutrition, recurrent aphthous stomatitis, elevated transaminases, and dental enamel hypoplasia. Celiac disease may also be associated with an autoimmune endocrinologic disorder such as thyroiditis. In addition, a variety of neuropsychiatric conditions such as depression, anxiety, peripheral neuropathy, ataxia, epilepsy with or without cerebral calcifications, and migraine headaches have been reported in individuals with celiac disease.

There is an existing classification of patients with putative subphenotypes. Whether these subphenotypes are clinically useful remains to be determined. These include the following:

**Classical celiac disease** is dominated by symptoms and sequelae of gastrointestinal malabsorption. The diagnosis is established by serological testing, biopsy evidence of villous atrophy, and improvement of symptoms on a gluten-free diet.

**Celiac disease with atypical symptoms** is characterized by few or no gastrointestinal symptoms, and extraintestinal

manifestations predominate. Recognition of atypical features of celiac disease is responsible for much of the increased prevalence, and now may be the most common presentation. As with classical celiac disease, the diagnosis is established by serologic testing, biopsy evidence of villous atrophy, and improvement of symptoms on a gluten-free diet.

**Silent celiac disease** refers to individuals who are asymptomatic but have a positive serologic test and villous atrophy on biopsy. These individuals usually are detected via screening of high-risk individuals, or villous atrophy occasionally may be detected by endoscopy and biopsy conducted for another reason.

**Latent celiac disease** is defined by a positive serology but no villous atrophy on biopsy. These individuals are asymptomatic, but later may develop symptoms and/or histologic changes.

## Complications of Celiac Disease

The complications of celiac disease typically occur after many years of disease and usually are observed in adults. Refractory celiac disease refers to persistence of symptoms and intestinal inflammation despite a gluten-free diet. This may occur in the context of ulcerative jejunitis, or it may be an early manifestation of intestinal lymphoma.

Most studies report an increased risk of non-Hodgkin lymphoma in celiac disease, but often do not distinguish between the classic celiac associated lymphoma (enteropathy associated T-cell lymphoma [EATL]) and other subtypes. EATL occurs primarily in people diagnosed during adulthood. Even with this increased risk, however, intestinal lymphoma is a very rare complication. Some evidence suggests that a gluten-free diet may reduce lymphoma risk. There is an increased risk of adenocarcinoma of the small intestine and some evidence that there may be an increased risk of carcinoma elsewhere in the gastrointestinal tract. All-cause mortality among those with clinically diagnosed celiac disease is about two times that of control populations.

## Who should be tested for celiac disease?

Individuals with gastrointestinal symptoms, including chronic diarrhea, malabsorption, weight loss, and abdominal distention, should be tested for celiac disease. Because celiac disease is a multisystem disorder, physicians should be aware of other conditions for which celiac disease testing should be considered.

Individuals without other explanations for signs and symptoms such as persistent elevations of transaminases, short stature, delayed puberty, iron-deficiency anemia, recurrent fetal loss, and infertility should be tested.

Other conditions for which celiac disease testing may be considered include irritable bowel syndrome, persistent aphthous stomatitis, autoimmune diseases, peripheral neuropathy, cerebellar ataxia, and dental enamel hypoplasia. Although individuals with celiac disease often present with osteoporosis, data do not indicate a significantly increased prevalence of celiac disease in the general population of people with osteoporosis. There are many other associated systemic symptoms that are not specific to celiac disease but for which celiac disease testing might be considered.

There are a number of populations at higher risk for celiac disease. These include individuals with type 1 diabetes mellitus, other autoimmune endocrinopathies, first- and second-degree relatives of individuals with celiac disease, and individuals with Turner syndrome. Individuals and physicians should be aware of the increased prevalence of celiac disease in these groups. Symptomatic individuals in these populations should be tested for celiac disease; for example, an individual with type 1 diabetes mellitus and unexplained hypoglycemia merits testing. Because current data do not indicate a clear outcome benefit for early detection and treatment of asymptomatic individuals in these groups, routine screening cannot be recommended at this time, but individual discussions regarding the benefits and consequences of testing are warranted.

Other populations at increased risk for celiac disease include individuals with Down syndrome and Williams syndrome. When individuals in these groups are unable to describe symptoms, screening may be appropriate and should be offered.

At this time, there are insufficient data to recommend screening of the general population for celiac disease.

For individuals who have been placed on a gluten-free diet without an appropriate diagnostic evaluation, testing should follow a gluten challenge. For those who decline to undergo a gluten challenge, the absence of DQ2 and DQ8 by HLA typing may help exclude the diagnosis. Resolution of symptoms on a gluten-free diet is not sufficient to diagnose celiac disease; however, there are no adverse nutritional outcomes associated with a carefully planned gluten-free diet.

## What is the management of celiac disease?

Treatment for celiac disease should begin only after a complete diagnostic evaluation including serology and biopsy.

The management of celiac disease is a gluten-free diet for life. A gluten-free diet is defined as one that excludes wheat, rye, and barley. These dietary grains contain the peptides or glutens known to cause celiac disease. Even small quantities of gluten may be harmful. Oats appear to be safe for use by most individuals with celiac disease, but their practical inclusion in a gluten-free diet is limited by potential contamination with gluten during processing. The strict definition of a gluten-free diet remains controversial due to the lack of an accurate method to detect gluten in food products and the lack of scientific evidence for what constitutes a safe amount of gluten ingestion.

The following are six key elements in the management of individuals affected by celiac disease:

**C**onsultation with a skilled dietitian

**E**ducation about the disease

**L**ifelong adherence to a gluten-free diet

**I**dentification and treatment of nutritional deficiencies

**A**ccess to an advocacy group

**C**ontinuous long-term followup by a multidisciplinary team

Learning about celiac disease and how to identify gluten-containing products is associated with improved self-management. Participation in an advocacy group is also an effective means of promoting adherence to a gluten-free diet and may provide emotional and social support. Health care providers should consider and treat vitamin and mineral deficiencies, including iron, calcium, phosphorus, folate, B12, and fat-soluble vitamins. Individuals with newly diagnosed celiac disease should undergo

screening for osteoporosis given the higher prevalence in this population. It is important to have a team-based approach to management. In addition to treatment by a physician and participation in a local advocacy group, consultation with a skilled dietitian is essential.

Following initial diagnosis and treatment, individuals should return for periodic visits with the physician and dietitian to assess symptoms and dietary adherence and monitor for complications. In children, this includes evaluation of growth and development. During these visits, health care providers can reinforce the benefits of adhering to a strict gluten-free diet for life.

Repeat serologic testing may be used to assess response to treatment but is unproven. These tests may take a prolonged time (up to 1 year) to normalize, especially in adults, and may not correlate with improved histology. Persistent elevated serological levels may suggest lack of adherence to a gluten-free diet or unintended gluten ingestion. Individuals who do not respond to a gluten-free diet require re-evaluation. No established approach exists to screen for complications of celiac disease including lymphoma and adenocarcinoma of the small bowel.

## **What are the recommendations for future research on celiac disease and related conditions?**

- Conduct a cohort study to determine the natural history of untreated celiac disease, especially “silent” celiac disease.
- Determine the response to gluten peptides in DQ2+/DQ8+ individuals without celiac disease. Determine which factors prevent disease.
- Identify which factors are involved in the induction of celiac disease in genetically susceptible individuals.
- Develop an animal model(s) of celiac disease that can be used to dissect pathogenic mechanisms.
- Determine prevalence of celiac disease in ethnic groups in the United States.
- Research prevention of celiac disease, e.g., timing of introduction of cereals in infants coupled to assessment of immune response (B-cell and T-cell) to gluters.
- Define the relationship between celiac disease and autoimmune and neuropsychiatric disorders.
- Identify non-HLA genetic modifiers that influence severity or phenotype of celiac disease.
- Develop noninvasive methodology to detect and quantify activity of celiac disease.
- Define the minimum safe exposure threshold of gluten in the diet relative to celiac disease.
- Develop alternatives to a gluten-free diet.
- Analyze the performance and cost effectiveness of serologic testing for celiac disease in the general population.

- Conduct research into screening methods for adenocarcinoma and lymphoma.
- Analyze the benefit of screening high-risk groups relevant to clinically important outcomes.
- Investigate the health-economic consequences of celiac disease.
- Identify and validate serologic assays for celiac disease diagnosis in young children.
- Investigate the quality of life of individuals with celiac disease.

## Conclusions

Celiac disease is an immune-mediated intestinal disorder with protean manifestations. Celiac disease is common, affecting 0.5 to 1.0 percent of the general population of the United States, but is greatly underdiagnosed. There are now specific and sensitive serologic tests available to aid in diagnosis that need to be more widely applied. The treatment of celiac disease remains a lifelong gluten-free diet, which results in remission for most individuals. The classic presentation of diarrhea and malabsorption is less common, and atypical and silent presentations are increasing. Most individuals are being seen by primary care providers and a broad range of specialists. Therefore, heightened awareness of this disease is imperative. Education of physicians, registered dietitians, and other health providers is needed.

The panel recommends the following:

- Education of physicians, dietitians, nurses, and the public about celiac disease by a trans-National Institutes of Health (NIH) initiative, to be led by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in association with the Centers for Disease Control and Prevention.
- Standardization of serologic tests and pathologic criteria for the diagnosis of celiac disease.
- Adoption of a standard definition of a gluten-free diet based on objective evidence such as that being developed by the American Dietetic Association.
- Development of an adequate testing procedure for gluten in foods and definition of standards for gluten-free foods in the United States to lay the foundation for rational food labeling.
- Formation of a federation of celiac disease societies, celiac disease interest groups, individuals with celiac disease and their families, physicians, dietitians, and other health care providers for the advancement of education, research, and advocacy for individuals with celiac disease.

# Consensus Development Panel

## **Charles O. Elson, M.D.**

*Panel and Conference  
Chairperson  
Professor of Medicine and  
Microbiology  
Vice Chair for Research  
Department of Medicine  
University of Alabama  
at Birmingham  
Birmingham, Alabama*

## **Martha Ballew, M.Ed., R.D., CNSD, LDN**

*Pediatric Nutrition  
Support Dietitian  
Division of Pediatric  
Gastroenterology,  
Hepatology, and Nutrition/  
Nutrition Services  
Vanderbilt University  
Medical Center  
Nashville, Tennessee*

## **John A. Barnard, M.D.**

*Professor of Pediatrics  
Divisions of Molecular Medicine  
and Gastroenterology  
The Ohio State University  
College of Medicine and  
Public Health  
Vice President of Scientific  
Affairs and Director of Center  
for Cell and Vascular Biology  
Columbus Children's  
Research Institute  
Columbus, Ohio*

## **Steven J. Bernstein, M.D., M.P.H.**

*Associate Professor of  
Internal Medicine  
Associate Research Scientist  
of Health Management  
and Policy  
University of Michigan  
Research Scientist  
Center for Practice Management  
and Outcomes Research  
Ann Arbor VA Healthcare System  
Ann Arbor, Michigan*

## **Irene J. Check, Ph.D., D(ABMLI)**

*Professor of Pathology  
The Feinberg School of Medicine  
Northwestern University  
Director  
Clinical Pathology Division  
Department of Pathology  
Evanston Northwestern  
Healthcare  
Evanston, Illinois*

## **Mitchell B. Cohen, M.D.**

*Professor of Pediatrics  
Division of Gastroenterology,  
Hepatology, and Nutrition  
Cincinnati Children's Hospital  
Medical Center  
University of Cincinnati  
Cincinnati, Ohio*

## **Sara Fazio, M.D.**

*Vice Chair  
Core I Medicine  
Clerkship Committee  
Harvard Medical School  
Division of General  
Internal Medicine  
Beth Israel Deaconess  
Medical Center  
Boston, Massachusetts*

## Speakers

**John F. Johanson, M.D., M.Sc.**

*Clinical Associate Professor*  
Department of Medicine  
University of Illinois College  
of Medicine, Rockford  
Rockford Gastroenterology  
Associates, Ltd.  
Rockford, Illinois

**Noralane M. Lindor, M.D.**

*Associate Consultant*  
Department of Medical Genetics  
Mayo Clinic  
Rochester, Minnesota

**Elizabeth Montgomery, M.D.**

*Associate Professor of  
Pathology and Oncology  
Director*  
Clinical Gastrointestinal  
Pathology  
Department of Pathology  
The Johns Hopkins Hospital  
Baltimore, Maryland

**Lisa H. Richardson**

*Consumer Representative  
National Chairperson of  
the Board Emeritus*  
Crohn's and Colitis Foundation  
of America, Inc.  
Houston, Texas

**Douglas Rogers, M.D.**

*Section Head of Pediatric  
Endocrinology*  
The Cleveland Clinic  
Cleveland, Ohio

**Sandeep Vijan, M.D., M.S.**

*Assistant Professor of  
Internal Medicine*  
University of Michigan  
*Physician-Scientist*  
Ann Arbor Veterans Affairs  
Health Services Research  
and Development  
Ann Arbor, Michigan

**Khalafalla O. Bushara, M.D.**

*Assistant Professor*  
Department of Neurology  
University of Minnesota  
Veterans Administration  
Medical Center  
Minneapolis, Minnesota

**Shelley Case, R.D.**

*Consulting Dietitian*  
Case Nutrition Consulting  
Regina, Saskatchewan, Canada

**Carlo Catassi, M.D., M.P.H.**

*Co-Medical Director*  
Division of Pediatric  
Gastroenterology  
and Nutrition  
Center for Celiac Research  
University of Maryland  
School of Medicine  
Baltimore, Maryland

**Paul J. Ciclitira, M.D., Ph.D., FRCP**

*Professor*  
The Rayne Institute  
St. Thomas' Hospital  
London, United Kingdom

**Pekka Collin, M.D., Ph.D.**

*Assistant Professor*  
Medical School  
University of Tampere  
Tampere, Finland

**Ann Cranney, M.D., M.Sc.**

*Associate Professor*  
Clinical Epidemiology Program  
Ottawa Health Research Institute  
Civic Hospital Site  
Ottawa, Ontario, Canada

**George S. Eisenbarth, M.D.**

*Executive Director*  
Barbara Davis Center for  
Childhood Diabetes  
University of Colorado Health  
Sciences Center  
Denver, Colorado

**Alessio Fasano, M.D.**

*Professor of Pediatrics,  
Medicine, and Physiology  
Director  
Mucosal Biology Research Center  
Center for Celiac Research  
University of Maryland  
School of Medicine  
Baltimore, Maryland*

**Peter H.R. Green, M.D.**

*Professor of Clinical Medicine  
Division of Digestive and  
Liver Disease  
Columbia University  
New York, New York*

**Ivor D. Hill, M.D.**

*Professor of Pediatrics  
Wake Forest University  
School of Medicine  
Winston-Salem, North Carolina*

**Edward J. Hoffenberg, M.D.**

*Associate Professor of Pediatrics  
Director  
Center for Pediatric Inflammatory  
Bowel Diseases  
Children's Hospital Denver  
University of Colorado  
School of Medicine  
Denver, Colorado*

**Martin F. Kagnoff, M.D.**

*Director  
Laboratory of Mucosal Immunology  
University of California  
at San Diego  
La Jolla, California*

**Ciaran P. Kelly, M.D.**

*Director  
Celiac Center  
Herrman L. Blumgart Firm Chief  
Director  
Gastroenterology  
Fellowship Training  
Associate Professor of Medicine*

Beth Israel Deaconess  
Medical Center  
Harvard Medical School  
Boston, Massachusetts

**Cynthia Kupper, R.D., C.D.**

*Executive Director  
Gluten Intolerance Group  
of North America  
Seattle, Washington*

**Joseph A. Murray, M.D.**

*Professor of Medicine  
Mayo Clinic  
Rochester, Minnesota*

**Michelle Maria Pietzak, M.D.**

*Director  
Center for Celiac Research–West  
Childrens Hospital Los Angeles  
Assistant Professor of Pediatrics  
University of Southern California  
Keck School of Medicine  
Los Angeles, California*

**Marian J. Rewers, M.D., Ph.D.**

*Professor  
Clinical Director  
Barbara Davis Center for  
Childhood Diabetes  
University of Colorado  
Health Sciences Center  
Denver, Colorado*

**Alaa Rostom, M.D., M.Sc., FRCPC**

*Assistant Professor  
Division of Gastroenterology  
The Ottawa Hospital,  
Civic Campus  
Ottawa, Ontario, Canada*

**John J. Zane, M.D.**

*Chairman and Professor  
of Dermatology  
University of Utah Health  
Sciences Center  
Salt Lake City, Utah*

## Planning Committee

### **Stephen P. James, M.D.**

*Planning Committee Chairperson  
Director*

Division of Digestive Diseases  
and Nutrition  
National Institute of Diabetes  
and Digestive and  
Kidney Diseases  
National Institutes of Health  
Bethesda, Maryland

### **David Atkins, M.D., M.P.H.**

*Chief Medical Officer  
Center for Practice and  
Technology Assessment  
Agency for Healthcare  
Research and Quality  
Rockville, Maryland*

### **Elsa A. Bray**

*Senior Advisor for  
Consensus Development  
Office of Medical Applications  
of Research  
Office of the Director  
National Institutes of Health  
Bethesda, Maryland*

### **Charles O. Elson, M.D.**

*Panel and Conference Chairperson  
Professor of Medicine  
and Microbiology  
Vice Chair for Research  
Department of Medicine  
University of Alabama  
at Birmingham  
Birmingham, Alabama*

### **James Everhart, M.D., M.P.H.**

*Chief  
Epidemiology and  
Clinical Trials Branch  
Division of Digestive Diseases  
and Nutrition  
National Institute of Diabetes  
and Digestive and  
Kidney Diseases  
National Institutes of Health  
Bethesda, Maryland*

### **Alessio Fasano, M.D.**

*Professor of Pediatrics,  
Medicine, and Physiology  
Director  
Mucosal Biology  
Research Center  
Center for Celiac Research  
University of Maryland  
School of Medicine  
Baltimore, Maryland*

### **Hugo Gallo-Torres, M.D.**

*Medical Team Leader  
Gastrointestinal Drugs  
Center for Biologics Evaluation  
and Research  
U.S. Food and Drug  
Administration  
Rockville, Maryland*

### **Gilman D. Grave, M.D.**

*Chief  
Endocrinology, Nutrition, and  
Growth Branch  
National Institute of Child Health  
and Human Development  
National Institutes of Health  
Bethesda, Maryland*

**Frank A. Hamilton, M.D., M.P.H.**

*Chief*  
Digestive Diseases Program  
Division of Digestive Diseases  
and Nutrition  
National Institute of Diabetes  
and Digestive and  
Kidney Diseases  
National Institutes of Health  
Bethesda, Maryland

**Van S. Hubbard, M.D., Ph.D.**

*Director*  
Division of Nutrition Research  
Coordination  
National Institute of Diabetes  
and Digestive and  
Kidney Diseases  
National Institutes of Health  
Bethesda, Maryland

**Martin F. Kagnoff, M.D.**

*Director*  
Laboratory of Mucosal  
Immunology  
University of California  
at San Diego  
La Jolla, California

**Ciaran P. Kelly, M.D.**

*Director*  
Celiac Center  
*Herrman L. Blumgart Firm Chief*  
*Director*  
Gastroenterology  
Fellowship Training  
*Associate Professor of Medicine*  
Beth Israel Deaconess  
Medical Center  
Harvard Medical School  
Boston, Massachusetts

**Barnett S. Kramer, M.D., M.P.H.**

*Director*  
Office of Medical Applications  
of Research  
Office of the Director  
National Institutes of Health  
Bethesda, Maryland

**Kelli K. Marciel, M.A.**

*Communications Director*  
Office of Medical Applications  
of Research  
Office of the Director  
National Institutes of Health  
Bethesda, Maryland

**Elaine Monarch**

*Founder*  
*Executive Director*  
Celiac Disease Foundation  
Studio City, California

**Joseph A. Murray, M.D.**

*Professor of Medicine*  
Mayo Clinic  
Rochester, Minnesota

**Lata S. Nerurkar, Ph.D.**

*Senior Advisor for Consensus  
Development*  
Office of Medical Applications  
of Research  
Office of the Director  
National Institutes of Health  
Bethesda, Maryland

**Karen Patrias, M.L.S.**

*Senior Resource Specialist*  
Public Services Division  
National Library of Medicine  
National Institutes of Health  
Bethesda, Maryland

**Jean Pennington, Ph.D., R.D.**

*Research Nutritionist*  
Division of Nutrition  
Research Coordination  
National Institute of Diabetes  
and Digestive and  
Kidney Diseases  
National Institutes of Health  
Bethesda, Maryland

**Marian J. Rewers, M.D., Ph.D.**

*Professor*  
*Clinical Director*  
Barbara Davis Center for  
Childhood Diabetes  
University of Colorado  
Health Sciences Center  
Denver, Colorado

**Susan Rossi, Ph.D., M.P.H.**

*Deputy Director*  
Office of Medical Applications  
of Research  
Office of the Director  
National Institutes of Health  
Bethesda, Maryland

**Annette Rothermel, Ph.D.**

*Program Officer*  
Clinical Immunology Branch  
Division of Allergy, Immunology,  
and Transplantation  
National Institute of Allergy  
and Infectious Diseases  
National Institutes of Health  
Bethesda, Maryland

**Jeffrey N. Siegel, M.D.**

*Acting Branch Chief*  
Immunology and Infectious  
Diseases Branch  
Office of Therapeutics Research  
and Review  
Center for Biologics Evaluation  
and Research  
U.S. Food and Drug  
Administration  
Rockville, Maryland

**Joseph T. Spence, Ph.D.**

*Director*  
Beltsville Human Nutrition  
Research Center  
Agriculture Research Service  
U.S. Department of Agriculture  
Beltsville, Maryland

**Carolyn Willard, M.L.S.**

*Librarian*  
National Library of Medicine  
National Institutes of Health  
Bethesda, Maryland

**Wyndham Wilson, M.D., Ph.D.**

Experimental Transplantation  
and Immunology Branch  
National Cancer Institute  
National Institutes of Health  
Bethesda, Maryland

## Conference Sponsors

### **National Institute of Diabetes and Digestive and Kidney Diseases**

Allen M. Spiegel, M.D.  
*Director*

### **Office of Medical Applications of Research**

Barnett S. Kramer, M.D., M.P.H.  
*Director*

## Conference Cosponsors

### **U.S. Food and Drug Administration**

Lester M. Crawford Jr.,  
D.V.M., Ph.D.  
*Acting Commissioner of  
Food and Drugs*

### **U.S. Department of Agriculture**

Ann M. Veneman, J.D., M.S.  
*Secretary*

### **National Institute of Child Health and Human Development**

Duane Alexander, M.D.  
*Director*

### **National Cancer Institute**

Andrew C. von Eschenbach, M.D.  
*Director*

### **National Institute of Allergy and Infectious Diseases**

Anthony S. Fauci, M.D.  
*Director*



U.S. DEPARTMENT OF HEALTH  
AND HUMAN SERVICES  
Public Health Service  
National Institutes of Health  
Office of Medical Applications of Research  
6100 Executive Boulevard, Room 2B03  
MSC 7523  
Bethesda, MD 20892-7523

---

Official Business  
Penalty for Private Use \$300

BULK RATE  
Postage & Fees  
PAID  
DHHS/NIH  
Permit No. G802